We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current PPCB market cap is 524.69k. The company's latest EPS is USD -0.0012 and P/E is 0.00.
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -3.49M | -1.81M | -1.99M | -1.78M | -1.54M |
| Net Income | -4.74M | -2.42M | -3.36M | -3.13M | -2.01M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 99k | 13k | 82k | 60k | 72k |
| Total Liabilities | 3.74M | 3.08M | 3.11M | 3.18M | 3.85M |
| Total Equity | -3.64M | -3.07M | -3.02M | -3.12M | -3.78M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -1.85M | -1.15M | -1.44M | -1.11M | -935k |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 1.89M | 1.06M | 1.49M | 1.11M | 942k |
| Market Cap | 524.69k |
| Price to Earnings Ratio | 0.00 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 1.75B |
| Average Volume (1 week) | 2.28M |
| Average Volume (1 Month) | 4.09M |
| 52 Week Change | -96.88% |
| 52 Week High | 0.02 |
| 52 Week Low | 0.0002 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Propanc Biopharma Inc (PK) |
| Address |
3411 silverside road tatnall building wilmington, delaware 19810 |
| Website | https:// |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
